Epsilon-V1-2 ε-V1-2; EAVSLKPT|cas:182683-50-7|西域试剂

Epsilon-V1-2 ε-V1-2; EAVSLKPT,98.18%

产品编号：Bellancom-P0154| CAS NO：182683-50-7| 分子式：C₃₇H₆₅N₉O₁₃| 分子量：843.96

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P0154	￥1800.00	杭州北京（现货）
Bellancom-P0154	￥3200.00	杭州北京（现货）
Bellancom-P0154	￥6400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Epsilon-V1-2 ε-V1-2; EAVSLKPT

产品介绍

Epsilon-V1-2 (ε-V1-2) 是一种 PKCε 衍生肽，是一种选择性 PKCε 抑制剂。Epsilon-V1-2 抑制 PKCε 的转运，但不抑制 α-，β- 和 δPKC 的转运。

生物活性

Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective PKCε inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC.

体外研究

Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide containing the site for its specific receptor for activated C kinase (RACK), inhibits translocation of PKCε and reduces insulin response to glucose.
Epsilon-V1-2 (ε-V1-2; 1 µM, 24 hours) treatment significantly inhibits Oleic acid (OA)-induced connexin 43 (Cx43) Ser368 phosphorylation and prevents OA-induced gap junction disassembly in cardiomyocytes.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice transplanted the hearts of FVB mice
Dosage:	20 mg/kg/day
Administration:	0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks
Result:	Significantly improved the beating score throughout the treatment.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice transplanted the hearts of FVB mice
Dosage:	20 mg/kg/day
Administration:	0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks
Result:	Significantly improved the beating score throughout the treatment.

性状

Solid

溶解性数据

In Vitro:

H₂O : 50 mg/mL (59.24 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1849 mL	5.9245 mL	11.8489 mL
5 mM	0.2370 mL	1.1849 mL	2.3698 mL
10 mM	0.1185 mL	0.5924 mL	1.1849 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶